FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣東康華醫療集團股份有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03689 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 84,394,000 | RMB | | 1 RMB | | 84,394,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 84,394,000 | RMB | | 1 RMB | | 84,394,000 | | 2. 股份分類 | 普通股 | 股份類別 | 其他 ...

Core Viewpoint - Kanghua Medical (03689) announced the resignation of Mr. Lv Yubo as a non-executive director and the appointment of Mr. Jiang Xiwen as a non-executive director, effective from October 17, 2025 [1] Company Changes - Mr. Lv Yubo will resign from his position as non-executive director [1] - Mr. Jiang Xiwen has been appointed as the new non-executive director [1] - Both changes will take effect on October 17, 2025 [1]

Core Viewpoint - Kanghua Medical (03689.HK) announced changes in its board of directors, with the resignation of non-executive director Lv Yubo and the appointment of Jiang Xiwen as a non-executive director, effective from October 17, 2025 [1] Group 1 - Lv Yubo has submitted his resignation as a non-executive director [1] - Jiang Xiwen has been appointed as a non-executive director [1] - The changes in the board will take effect on October 17, 2025 [1]

Core Viewpoint - Kanghua Medical (03689) announced the resignation of Mr. Lv Yubo as a non-executive director and the appointment of Mr. Jiang Xiwen as a non-executive director, effective from October 17, 2025 [1] Company Changes - Mr. Lv Yubo has submitted his resignation as a non-executive director [1] - Mr. Jiang Xiwen has been appointed as a non-executive director [1] - Both changes will take effect on October 17, 2025 [1]

（於中華人民共和國註冊成立的股份有限公司） （股份代號：3689） 董事名單及董事的職責與職能 廣東康華醫療集團股份有限公司 GUANGDONG KANGHUA HEALTHCARE GROUP CO., LTD.* 蔣析文先生 獨立非執行董事 陳可冀醫生 陳星能先生 林小玲女士 董 事 會 已 成 立 三 個 委 員 會，該 等 委 員 會 的 成 員 載 列 如 下。 | | 董事會委員會 | | | | | --- | --- | --- | --- | --- | | 董 事 | | 審核委員會 | 薪酬委員會 | 提名委員會 | | 王君揚先生 | | | | C | | 王愛勤女士 | | | M | | | 陳可冀醫生 | | M | | M | | 陳星能先生 | | C | C | | | 林小玲女士 | | M | M | M | 附 註： C: 相關董事會委員會的主席 M: 相關董事會委員會的成員 廣 東 康 華 醫 療 集 團 股 份 有 限 公 司（「本公司」）董 事 會（「董事會」）的 成 員 載 列 如 下。 執行董事 王君揚先生 （主 席） 陳旺枝先生 王偉雄先生 王愛勤女士 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 廣東康華醫療集團股份有限公司 GUANGDONG KANGHUA HEALTHCARE GROUP CO., LTD.* – 1 – (i) 呂 玉 波 先 生 已 提 呈 辭 任 非 執 行 董 事；及 (ii) 蔣 析 文 先 生 已 獲 委 任 為 非 執 行 董 事。 上 述 變 更 將 自 二 零 二 五 年 十 月 十 七 日 起 生 效。 2. 董事委任 董 事 會 已 於 二 零 二 五 年 十 月 十 七 日 根 據《中 華 人 民 共 和 國 公 司 法》及 本 公 司 公 司 章 程 之 規 定 召 開 會 議。董 事 會 欣 然 宣 佈，因 應 呂 先 生 辭 任，蔣 析 文 先 生（「蔣先生」）獲 委 任 為 非 執 行 董 事，初 始 任 期 自 二 零 二 五 年 十 月 十 七 日 （「生效日期」）起 計，直 至 本 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣東康華醫療集團股份有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03689 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 84,394,000 | RMB | | 1 RMB | | 84,394,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 84,394,000 | RMB | | 1 RMB | | 84,394,000 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類 ...

GUANGDONG KANGHUA HEALTHCARE GROUP CO., LTD.* Guangdong Kanghua Healthcare Group Co., Ltd.* (the "Company") - Notice of Publication of 2025 Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company has been published in English and Chinese languages and are available on the website of The Stock Exchange of Hong Kong Limited ("HKEX") at www.hkexnews.hk and the Company's website at www.kanghuagp.com. If you have any difficulty in receiving or gaining access to ...

(Stock Code 股份代號: 3689) N O T I F I C AT I O N L E T T E R 通 知 信 函 GUANGDONG KANGHUA HEALTHCARE GROUP CO., LTD.* 廣東康華醫療集團股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） Dear registered shareholder(s), Guangdong Kanghua Healthcare Group Co., Ltd.* (the "Company") - Notice of Publication of 2025 Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company has been published in English and ...

Financial Performance - Revenue for the six months ended June 30, 2025, was RMB 981,535,000, a slight decrease of 0.3% compared to RMB 984,518,000 in 2024[9] - Gross profit increased by 8.3% to RMB 158,533,000, with a gross profit margin of 16.2%, up from 14.9% in the previous year[9] - Profit for the period attributable to owners of the Company was RMB 41,642,000, compared to a loss of RMB 19,542,000 in 2024[9] - Adjusted EBITDA rose by 38.7% to RMB 126,666,000, reflecting improved operational efficiency[9] - Basic earnings per share increased to 12.5 RMB cents, compared to a loss of 5.8 RMB cents in the same period last year[9] - The Group recorded a consolidated profit of RMB 32.6 million, compared to a loss of RMB 24.7 million for the same period last year, primarily due to the disposal of 55% equity interest in Kangxin Hospital[42] - Adjusted EBITDA increased by 38.7% to RMB 126.7 million, compared to RMB 91.3 million in the six months ended June 30, 2024, reflecting strong core operations[54] - The Group recorded a profit of RMB 32.6 million for the reporting period, compared to a loss of RMB 24.7 million for the six months ended June 30, 2024[150] - Profit attributable to shareholders was RMB 41.6 million, reversing from a loss of RMB 19.5 million in the same period last year[153] - The Group's profit before tax (IFRS measure) was RMB 52.98 million, compared to a loss of RMB 3.1 million for the same period last year[157] Operational Metrics - The number of outpatient visits in 2025 was 651,400, an increase from 577,400 in 2024[15] - Overall patient visits in the hospital services segment decreased by 12.8% compared to the same period last year, including the impact of the de-consolidation of Kangxin Hospital[43] - The total number of inpatient visits decreased to 35,311, representing a period-on-period decrease of 7.0%[55] - The total number of outpatient visits decreased to 651,350, a decline of 14.0%[59] - The total number of surgical operations rose to 25,898, marking a significant increase of 31.5%[59] - Inpatient visits at Kanghua Hospital decreased by 7.0% to 35,311, while outpatient visits dropped by 14.0% to 651,350[61] - The total number of surgical operations performed was 25,898, representing a 31.5% increase compared to 19,692 surgeries in the same period last year[72] Revenue Segmentation - Revenue from the hospital services segment was RMB873.3 million, representing a decrease of 0.8% compared to RMB880.8 million for the same period last year[43] - Revenue from the rehabilitation and other related healthcare services segment was RMB58.6 million, a decrease of 1.9% compared to RMB59.7 million for the same period last year[49] - Revenue from inpatient healthcare services amounted to RMB521.0 million, representing a period-on-period decrease of 0.3% and accounting for 53.1% of total revenue[116] - Revenue from outpatient healthcare services amounted to RMB303.9 million, representing a period-on-period decrease of 4.8% and accounting for 31.0% of total revenue[116] - Revenue from haemodialysis services amounted to RMB42.7 million, representing a period-on-period increase of 15.1% and accounting for 4.4% of total revenue[119] - Revenue from rehabilitation hospitals and other healthcare services decreased by 11.6% to RMB 25.0 million, while revenue from rehabilitation center services increased by 6.9% to RMB 33.6 million[80] - Revenue from postpartum care services amounted to RMB4.1 million, reflecting a strategic restructuring for better performance measurement[65] - Revenue from VIP healthcare services amounted to RMB 52.2 million, a decline of 2.4% from RMB 53.5 million in the same period last year, attributed to the economic environment in the Dongguan region[73] Cost Management - The Group's administrative expenses and finance costs have substantially decreased due to cost-saving measures implemented during the Reporting Period[42] - The Group's finance costs included bank loan interest of RMB 5.6 million, down from RMB 18.7 million in the previous period[148] - Total staff-related costs decreased slightly by 1.0% compared to the prior period, primarily due to the financial impact from the disposal of Kangxin Hospital[132] - Staff costs, repairs and maintenance expenses, and office expenses decreased by 21.1%, 23.9%, and 35.2% respectively compared to the same period last year[144] - The cost of revenue for the hospital services segment decreased to RMB728.5 million, representing a period-on-period decrease of 2.6% due to the disposal of 55% equity interest in Kangxin Hospital[124] Strategic Initiatives - Future outlook includes plans for market expansion and potential acquisitions to enhance service offerings[9] - The Group is investing in new technologies to improve patient care and operational efficiency[9] - The Group plans to enhance outpatient management to improve patient visits, particularly in pediatrics and respiratory care[97] - The Group aims to strengthen social security payment management systems to address revenue growth pressures from payment rate adjustments[99] - The Group will focus on high-end medical services to meet rising patient expectations for quality medical experiences[98] - The Group is actively collaborating with social insurance agencies to promote diversified payment models in response to tightening social insurance payment quotas[101] Market Trends - The aging population in China is significantly driving up healthcare demand, particularly for geriatric care and chronic disease management services[35] - The healthcare industry faced unprecedented operational pressure in 2025, impacting patient visits and revenue generation[62] - The private rehabilitation market is expanding, driven by an increasing elderly population, but competition is intensifying with more private clinics emerging[49] - Increased regional competition in medical specialties has contributed to a decrease in business volume at Kanghua Hospital and Renkang Hospital[116] Asset Management - The Group's cash flow from operations continues to generate steady income, supporting its liquidity and financial resource needs for at least the next twelve months[188] - Cash and cash equivalents reached RMB359.7 million as of June 30, 2025, an increase from RMB242.6 million as of December 31, 2024, indicating a strong liquidity position[188] - The Group's investment property, primarily the phase 1 medical facility of Kangxin Hospital, was revalued at RMB222.0 million, with a surplus of RMB20.1 million recognized[170] - The Group recognized a gain on the disposal of Kangxin Hospital of approximately RMB 19.5 million and recorded the remaining 45% interest as an associate at a fair value of RMB 23.2 million[175]